CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that researchers will present data from a long-term follow-up study of the efficacy of Soliris® (eculizumab) in preventing thrombotic microangiopathy (TMA) events in patients with atypical hemolytic uremic syndrome (aHUS). Researchers will also present a post-hoc analysis of the safety of Soliris in pediatric patients with aHUS, as well as an update from the Global aHUS Registry.
Help employers find you! Check out all the jobs and post your resume.
